ACT up +4.89% percent Today $ACT High is at 264.00 and the

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 10:35 AM

ACT up +4.89% percent Today $ACT High is at 264.00 and the Low 249.86 with current volume of 3,840,428.

Recent News posted below.

Actavis Inc ACT other info.
http://investorshangout.com/Actavis-Inc-ACT-53105/

ACT Actavis Inc Recent Headline News

Will Pfizer's Dividend Be Safe?
Todd Campbell, The Motley Fool - Motley Fool - 1 hr 4 mins ago
Source: Pfizer via Facebook. Pfizer (NYSE: PFE) may be one of the planet's largest drugmakers, but it's been navigating a series of sales-crunching patent expirations that has investors wondering if the company's dividend payout will remain...
ACT: 260.29 (+12.35), PFE: 30.39 (+0.07), TEVA: 57.50 (+0.26)

Winners And Losers In The Allergan Valeant Actavis Melee; Also, Will Bill Ackman Lose His Profit?
Uncommon Profit Investor - at Seeking Alpha - 2 hrs 1 min ago

AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.40 (+12.46)

Here Are Some Big Caps Poised To Make Gains
at Investor's Business Daily - Mon Nov 17, 5:45PM CST
Several Big Cap 20 stocks have recently broken out of bases, but are still within buy range, or are building new bases and could be good additions to a watch list. Alexion Pharmaceuticals (ALXN) has pulled back and is within the 5% buy zone. The...
AGN: 212.09 (+2.89), ACT: 260.28 (+12.34), VRX: 142.47 (+5.74), V: 250.41 (+0.61), ALXN: 190.00 (+3.22), CTSH: 53.00 (-0.06), MA: 83.58 (+0.38), ADS: 282.20 (+1.32)

Bristol-Myers Squibb Reports Positive Opdivo Phase III Data - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 5:20PM CST
Bristol-Myers Squibb Company announced encouraging data from the phase III CheckMate - 066 study on immuno-oncology drug Opdivo.
AGN: 212.09 (+2.89), ACT: 260.28 (+12.34), AMAG: 35.84 (+1.08), BMY: 58.76 (+0.33)

After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 4:40PM CST

URBN: 28.29 (-2.54), DHX: 11.38 (+0.12), ACT: 260.43 (+12.49), OME: 12.60 (-2.38), CLVS: 53.47 (+0.14), AVB: 157.72 (-0.44), PF: 32.50 (-1.22), RMTI: 10.24 (-0.34), GLW: 20.47 (+0.11), FOLD: 6.35 (-0.35)

Actavis to spend $66 billion on Allergan
By TOM MURPHY - AP - Mon Nov 17, 4:01PM CST
Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products.
1 Comment
DRTX: 24.16 (+0.41), AGN: 212.15 (+2.95), ACT: 260.25 (+12.31), VRX: 142.47 (+5.74), MRK: 59.63 (+0.17), VRX.TO: 160.18 (+5.78)

Stocks End Mixed As Allergan Jumps On Actavis Deal
at Investor's Business Daily - Mon Nov 17, 3:16PM CST
Major averages pared losses from a late-morning slump to end mixed amid big merger deals and weak economic data. The S&P 500 and Dow Jones industrial average closed fractionally higher, while the Nasdaq fell 0.4%. Volume ran lower across the board in...
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), SAFM: 87.09 (+2.16), PPC: 31.27 (+0.33), MIK: 21.76 (+0.11), TSN: 42.79 (-0.24)

Stock Market Today: Japan Recession Keeps Markets From Celebrating Deals Deluge
at The Street - Mon Nov 17, 3:15PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies momentarily distracts Wall Street from worrying news Japan has fallen into recession in its third quarter.
AMZN: 328.74 (+5.69), HAS: 55.99 (-0.38), ACT: 260.25 (+12.31), VRX: 142.47 (+5.74), JIVE: 6.42 (+0.05), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), DWA: 22.31 (unch), AGN: 212.15 (+2.95), LNKD: 223.87 (+0.59), BHI: 66.13 (+0.90), CRM: 63.20 (+0.69)

Stocks Mixed In Afternoon; Allergan Jumps To New High
at Investor's Business Daily - Mon Nov 17, 2:13PM CST
Stocks remained mixed late Monday afternoon as investors weighed a spate of merger activity against news that Japan fell into a recession. The Dow Jones industrial average and the S&P 500 were each up 0.1%, while the Nasdaq was down 0.3%. Volume was...
AGN: 212.15 (+2.95), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), LNKD: 223.87 (+0.59), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), BHI: 66.13 (+0.90), Z: 120.50 (+2.64)

Stock Market Today: Stocks Are Mixed as Corporate Deals Offset Japan's Recession
at The Street - Mon Nov 17, 12:16PM CST
Wheelings and dealings from top pharmaceutical giants and energy companies distract Wall Street from worrying news Japan had fallen into recession in its third quarter.
AGN: 212.15 (+2.95), HAS: 55.99 (-0.38), AMZN: 328.82 (+5.77), VRX: 142.47 (+5.74), ACT: 260.25 (+12.31), LNKD: 223.87 (+0.59), JIVE: 6.42 (+0.05), FB: 74.68 (+0.44), HAL: 49.96 (+0.73), DWA: 22.31 (unch), CRM: 63.21 (+0.70), BHI: 66.13 (+0.90)

Pershing Square wins big on Actavis buy
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 11:22AM CST

AGN: 212.15 (+2.95), ACT: 260.24 (+12.30), VRX: 142.47 (+5.74)

Cramer: Investors Should Ignore Analysts' Calls on Hotel, Other Stocks
at The Street - Mon Nov 17, 10:32AM CST
Analysts have been growing pessimistic on several high quality stocks and sectors. Investors should use weakness as a buying opportunity instead, Cramer said.
AGN: 212.15 (+2.95), ACT: 260.24 (+12.30), PG: 87.79 (-0.05), MAR: 76.89 (-0.28), HOT: 77.44 (+0.59)

Allergan's $66 Billion Actavis Deal is Still a Win for Bill Ackman
at The Street - Mon Nov 17, 9:59AM CST
Valeant says it can't justify $219 a share offer to shareholders.
ZTS: 43.45 (-0.78), AGN: 212.06 (+2.86), VRX: 142.47 (+5.74), ACT: 260.24 (+12.30)

Stock Market Today: Stocks Shrug Off Japan's Recession as Deals Dominate Day
at The Street - Mon Nov 17, 9:40AM CST
U.S. stocks recover from earlier lows triggered by Japan's recession. Deals news about Baker Hughes and Allergan dominate headlines.
AGN: 212.06 (+2.86), HAS: 55.97 (-0.40), ACT: 260.24 (+12.30), HAL: 49.96 (+0.73), DWA: 22.31 (unch), BHI: 66.12 (+0.89)

ALLERGAN, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
PR Newswire - Mon Nov 17, 9:32AM CST
Rigrodsky & Long, P.A.:
AGN: 212.05 (+2.85), ACT: 260.24 (+12.30)

Actavis Nabs Allergan For $66 Billion; Valeant Folds
at Investor's Business Daily - Mon Nov 17, 9:17AM CST
One of the most widely rumored deals in pharma came to fruition Monday, as Actavis (ACT) agreed to acquire Allergan (AGN) for $66 billion in cash and stock. Allergan stock was up more than 7%, near 213, and Actavis stock up nearly 4%, near 253, in...
AGN: 212.05 (+2.85), VRX: 142.47 (+5.74), ACT: 260.24 (+12.30)

Time to move on: Valeant chief says $219 too rich
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:13AM CST

ACT: 260.25 (+12.31), VRX: 141.71 (+4.98)

Valeant Comments On Allergan Announcement
PR Newswire - Mon Nov 17, 8:29AM CST
Valeant Pharmaceuticals International, Inc. (NYSE/TSX: VRX) today commented on the announcement that Allergan, Inc. (NYSE: AGN) and Actavis plc (NYSE: ACT) have entered into a definitive agreement under which Actavis will acquire all outstanding shares of Allergan stock.
AGN: 212.13 (+2.93), ACT: 260.25 (+12.31), VRX: 141.71 (+4.98), VRX.TO: 160.18 (+5.78)

It's official: Actavis buys Allergan
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 8:26AM CST

AGN: 212.03 (+2.83), ACT: 260.29 (+12.35)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Finzly Launches AI Security Layer Amid Rising Threats

Bank Security in the Age of AI You'd think banks, of all places, were impenetrable fortresses. But these days, they're more like digital targets. With AI-driven attacks becoming as common as morning coffee, Finzly's introducing Assure, an AI-powered security and assurance layer. It's about as timely as ever, given the 89% spike in AI-enabled attacks seen last year. When...

Flex Acquires EPC Power in a $4.4 Billion Deal

An Acquisition with Enormous Implications Folks, if you haven't been paying attention, you're missing out on a seismic shift. EPC Power's sale to Flex for a hefty $4.4 billion isn't just another transaction; it's a clear signal of where the future's headed, especially if you're plugged into the energy or tech sectors. With the way AI is guzzling power like a thirsty...

Yardi Virtuoso AI to Shine at CAIC 2026 Toronto

The Scene in Toronto: Yardi's Big AI Showcase There's no denying it—Artificial Intelligence has muscled its way into practically every corner of the business world, and now it's making waves in real estate. Yardi, a familiar name in real estate tech circles, is gearing up to flaunt its Yardi Virtuoso Enterprise at the Canadian Apartment Investment Conference (CAIC) in...

Allison Ng Earns Prestigious NAPABA 'Best Under 40' Award

Allison Ng's Achievement: Beyond the Legal Grind Without warning, the legal world has another star rising up through its ranks, and this time it's Allison Ng catching the spotlight. She’s tucked away in Greenberg Traurig’s Atlanta office, plugging away in pharmaceutical and medical device litigation. But every now and then, these legal eagles get a chance to spread...

Little Sunshine's Opens New School in Peoria, AZ

Betting On Early Childhood Education Little Sunshine's Playhouse breaks ground on a fresh hub of learning in Peoria, Arizona, and this is no small playdate. It's the dawn of another preschool institution aiming to mold the early years of countless kiddos. The gears turning behind this development are impressive by themselves, but it's what it means for Peoria's families...

LV Petroleum Expands Footprint with Key Acquisitions

LV Petroleum's Bold Moves in July Ever seen a company expand across four states in a blink? LV Petroleum's been hustling like a player with a fresh hand of aces. They shut July down with restaurant openings and a fancy new travel center under their belt in states as spread out as Arizona, Texas, Nevada, and Ohio. Now that's a wide net they're casting, all in the name of...

Innovation Drives New Asia-Pacific Opportunities

A Glimpse Into The Future: Asia-Pacific's Tech Landscape There's a unique transformation bubbling across the Asia-Pacific scene, with young minds pushing the envelope on technology and innovation. Take Nathapol's team from Thailand, for example. They're merging bionic tech with drones for disaster relief—bold, ambitious, and nearly clinching glory at the Lancang-Mekong...

Truist Revolutionizes Banking with 2 Billion Insights

A New Frontier in Banking Truist is out here flipping the script in digital banking, pushing a staggering 2 billion AI-driven insights since 2023. Imagine that—two billion insights 'till now, providing the kind of financial street smarts that help folks feel less like they're lost at sea and more like they're the captain of their own financial ship, all thanks to Truist...

Decoding Historic Home Buys: Tips for New Owners

Realities Behind the Rustic Facade Picture this: you’re standing in front of a crumbling beauty with crown molding and character oozing from its very walls. Now what? It's easy to get swept away by the allure of a historic home, but there's gritty work to be done under those charming facades. Enter Debi Beiland of Limestone Properties over in Maysville, KY. She’s got...

Médunik Canada Boosts Dravet Syndrome Support with Biocodex

Breaking Down the Exclusive Médunik-Biocodex Partnership Listen, when a company like Médunik Canada, firmly rooted in Blainville, QC, throws its weight behind a rare disease drug like Diacomit®, folks in the industry take notice. Their recent handshake with Biocodex isn't just small talk; it opens doors to change how Dravet syndrome is managed across Canada. This new...